Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 2;9(11):e17735.
doi: 10.2196/17735.

Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial

Lubaba Shahrin  1 , Mohammod Jobayer Chisti  1 , Abu Sadat Mohammad Sayeem Bin Shahid  1 , Abu Sayem Mirza Mohammad Hasibur Rahman  1 , Md Zahidul Islam  1 , Farzana Afroze  1 , Sayeeda Huq  1 , Tahmeed Ahmed  1
Affiliations

Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial

Lubaba Shahrin et al. JMIR Res Protoc. .

Abstract

Background: Pneumonia causes about 0.9 million deaths worldwide each year. The World Health Organization (WHO) guidelines for the standard management of severe pneumonia requires parenteral ampicillin every 6 hours and once-daily parenteral gentamicin for 5 to 7 days. Although this treatment has contributed to the reduction of mortality, it requires nursing interventions every 6 hours for 7 days. Further intervention trials should be conducted to search for alternate antibiotics with better adherence, reduced cost, and reduced hospital stay. Parenteral amoxicillin is an effective alternative to ampicillin, as it has a longer half-life and broader coverage.

Objective: The aim of this clinical trial is to compare the efficacy of a dose of injectable amoxicillin every 12 hours plus a once-daily dose of injectable gentamicin with a dose of injectable ampicillin every 6 hours plus a once-daily dose of injectable gentamicin in children hospitalized for severe pneumonia.

Methods: This randomized, controlled, open-label, noninferiority trial is being conducted in Dhaka Hospital of the International Centre for Diarrheal Disease Research, Bangladesh. A sample size of 308 children with severe pneumonia will give adequate power to this study. Children aged 2 to 59 months are randomized to either intravenous ampicillin or intravenous amoxicillin, plus intravenous gentamicin in both study arms. The monitoring of the patients is carried out according to the WHO protocol for the treatment of severe pneumonia. The primary objective is the rate of treatment failure, defined by the persistence of danger signs of severe pneumonia beyond 48 hours or deterioration within 24 hours of initiation of the therapy. The secondary objectives are (1) improvement in or the resolution of danger signs since enrollment, (2) length of hospital stay, (3) death during hospitalization, and (4) rate of nosocomial infections.

Results: Enrollment in the study started on January 1, 2018, and ended on October 31, 2019. Data entry and analysis are in progress. Findings from the study are expected to be disseminated in October 2020.

Conclusions: Our study's findings will improve compliance with the use of antibiotics that require less frequent doses for the treatment of severe pneumonia.

Trial registration: ClinicalTrials.gov NCT03369093; https://clinicaltrials.gov/ct2/show/NCT03369093.

International registered report identifier (irrid): DERR1-10.2196/17735.

Keywords: amoxicillin; children; randomized controlled trial, Bangladesh; severe pneumonia; treatment failure.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) figure showing the schedule of enrollment, interventions, and assessments. IV: intravenous.
Figure 2
Figure 2
Flowchart for the proposed randomized controlled trial. IM: intramuscular; IV: intravenous.
See this image and copyright information in PMC

References

    1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan 31;385(9966):430–40. doi: 10.1016/S0140-6736(14)61698-6. - DOI - PubMed
    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EAF, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 01;375(9725):1545–55. doi: 10.1016/S0140-6736(10)60206-1. http://europepmc.org/abstract/MED/20399493 - DOI - PMC - PubMed
    1. Feikin DR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JAG. The Enduring Challenge of Determining Pneumonia Etiology in Children: Considerations for Future Research Priorities. Clin Infect Dis. 2017 Jun 15;64(suppl_3):S188–S196. doi: 10.1093/cid/cix143. http://europepmc.org/abstract/MED/28575369 - DOI - PMC - PubMed
    1. Fischer Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013 Apr 20;381(9875):1405–1416. doi: 10.1016/S0140-6736(13)60222-6. http://europepmc.org/abstract/MED/23582727 - DOI - PMC - PubMed
    1. Gilani Z, Kwong YD, Levine OS, Deloria-Knoll M, Scott JAG, O'Brien KL, Feikin DR. A literature review and survey of childhood pneumonia etiology studies: 2000-2010. Clin Infect Dis. 2012 Apr;54 Suppl 2:S102–8. doi: 10.1093/cid/cir1053. http://europepmc.org/abstract/MED/22403223 - DOI - PMC - PubMed

Associated data